BioCentury
ARTICLE | Company News

ExonHit genomics, pharmacogenetics news

March 12, 2012 7:00 AM UTC

ExonHit joined the RESPONSIFY consortium and received a €418,000 ($551,509) grant under the European Commission's Framework Programme 7 (FP7). ExonHit will work with academic and industry partners to develop its Genome Wide SpliceArray (GWSA) technology to analyze cancer patients' transcriptomic profiles. RESPONSIFY, which comprises 12 partners, was formed to develop IVD tests to predict response to cancer chemotherapies Herceptin trastuzumab, a humanized mAb against epidermal growth factor receptor 2 ( EGFR2; HER2; ErbB2; neu), and Avastin bevacizumab, a humanized mAb against VEGF. ExonHit will be responsible for seeking IP protection and CE Mark approval, as well as commercialization of tests identified on its technology. ExonHit said that the grant will cover 70% of its costs for the project. The GWSA microarray technology monitors RNA splice variants. The consortium is funded by a total grant of €6 million ($7.9 million). ...